Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial

Who is this study for? Adult female patients up to age 70 with breast cancer
Status: Recruiting
Location: See all (7) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• patients developing breast cancer as confirmed by X-ray examination, cancer tissue negative for estrogen receptor, progesterone receptor and HER2, and tumor stage II-III;

• estimated survival \> 3 months;

• presence of clinically measurable lesions;

• Karnofsky functional status score ≥ 70;

• normal routine blood test results, normal liver and kidney function, and near normal electrocardiographic manifestations;

• age at 18-70 years.

Locations
Other Locations
China
The Second Hospital of Jilin University
RECRUITING
Changchun
Dalian Municipal Central Hospital
RECRUITING
Dalian
Cancer Hospital Affiliated to Harbin Medical University
RECRUITING
Harbin
Panjin Liaohe Oilfield Gem Flower Hospital
RECRUITING
Panjin
Liaoning Cancer Hospital & Institute
RECRUITING
Shenyang
Shengjing Hospital of China Medical University
RECRUITING
Shenyang
The Fourth Affiliated Hospital of China Medical University
RECRUITING
Shenyang
Contact Information
Primary
Xi Gu, M.D.
jadegx@163.com
+86 18940255116
Time Frame
Start Date: 2021-07-19
Estimated Completion Date: 2026-11-30
Participants
Target number of participants: 110
Treatments
Experimental: Trial group
55 cases of triple-negative breast cancer will be assigned into a trial group.
Active_comparator: Control group
55 cases of triple-negative breast cancer will be assigned into a control group.
Related Therapeutic Areas
Sponsors
Leads: Shengjing Hospital

This content was sourced from clinicaltrials.gov